Objective:To provide basis for civil aviation medical appraisal and aviation health support work by analyzing the classic case of ophthalmic suspension in civil aviation pilots and summarizing the experience.Methods:A grounding case of civil aviation pilot, who was developed central serous chorioretinopathy (CSC) and glucocorticoid induced cataract (GIC) after glucocorticoid (GC) treatment for chronic nephritis, was retrospective analyzed and the relevant literatures were reviewed.Results:The patient, a 36-year-old male pilot of a B737 airline fleet, was diagnosed with chronic glomerulonephritis on November 8, 2020. He was treated with GC, cyclophosphamide, cyclosporine, and other medications. In March 2021, he was diagnosed with bilateral CSC and bilateral GIC after ophthalmology consultation due to his continually decreased binocular vision. The patient was treated with local retinal photocoagulation in both eyes and phacoemulsification and intraocular lens implantation for cataract in the right eye. After treatment, there was no improvement in the visual function of the right eye, and the visual function did not meet the corresponding medical standards of the medical examination certificate, resulting in he was unqualified for flight.Conclusions:Civil aviation pilots should pay attention to the possible adverse reactions that may be caused by the use of GC in the eyes. It is necessary to use GC scientifically and reasonably, and actively treat the induced CSC and GIC. Aviation physicians should strengthen health guidance, intervention, and tracking management for the pilots suffering from the above-mentioned eye diseases, and do a good job in promoting their health management.

Objective:To provide basis for civil aviation medical appraisal and aviation health support work by analyzing the classic case of ophthalmic suspension in civil aviation pilots and summarizing the experience.Methods:A grounding case of civil aviation pilot, who was developed central serous chorioretinopathy (CSC) and glucocorticoid induced cataract (GIC) after glucocorticoid (GC) treatment for chronic nephritis, was retrospective analyzed and the relevant literatures were reviewed.Results:The patient, a 36-year-old male pilot of a B737 airline fleet, was diagnosed with chronic glomerulonephritis on November 8, 2020. He was treated with GC, cyclophosphamide, cyclosporine, and other medications. In March 2021, he was diagnosed with bilateral CSC and bilateral GIC after ophthalmology consultation due to his continually decreased binocular vision. The patient was treated with local retinal photocoagulation in both eyes and phacoemulsification and intraocular lens implantation for cataract in the right eye. After treatment, there was no improvement in the visual function of the right eye, and the visual function did not meet the corresponding medical standards of the medical examination certificate, resulting in he was unqualified for flight.Conclusions:Civil aviation pilots should pay attention to the possible adverse reactions that may be caused by the use of GC in the eyes. It is necessary to use GC scientifically and reasonably, and actively treat the induced CSC and GIC. Aviation physicians should strengthen health guidance, intervention, and tracking management for the pilots suffering from the above-mentioned eye diseases, and do a good job in promoting their health management.